Brief: Moleculin Announces Positive Phase 1 Data For WP1066 In Pediatric Brain Tumors
17/12/2025 14:43
Dec 17 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN ANNOUNCES POSITIVE RESULTS FROM PHASE 1 CLINICAL TRIAL EVALUATING WP1066 FOR THE TREATMENT OF PEDIATRIC RECURRENT MALIGNANT BRAIN TUMORS MOLECULIN BIOTECH INC - WP1066 FOUND SAFE AND EFFECTIVE, WARRANTING PHASE 2 TRIAL Source text: ID:nGNX612ST4 Further company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM